Drug intelligence / Profile preview

5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide

Development stage: Unknown
Lead developer: Amgen
Modality: Small Molecules

Overview

This compound is a synthetic small molecule with the chemical formula C23H24ClN3O5 and a molecular weight of approximately 457.91 g/mol[1][2][6]. It is classified as an isoxazole derivative and has been referenced in chemical databases such as PubChem (CID: 135525416), DrugBank (DB06961), ChEMBL (CHEMBL398346), and ChemSpider (ID:22376200)[1][2][3][6]. The compound features a morpholine ring and dihydroxychlorophenyl moiety attached to an isoxazole core. There are no approved therapeutic indications or clinical trial data available for this molecule; it remains experimental with no known pharmacological action or mechanism of action reported in public sources[2][7]. Its structure suggests potential for protein interaction studies—specifically with heat shock proteins HSP90α/β—but there are no confirmed biological targets or mechanisms described in the literature[3][4].

Other names: N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholinylmethyl)phenyl]-1,2-isoxazolecarboxamideCAS 747412–66–4

Targets

HSP90AA1 (Heat shock protein HSP90-alpha)

Beyond the preview

Go deeper on 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide.

Explore the full profile